

At Sri Krishna Pharma, we take a need-focused, portfolio-based approach to meeting customer requirements. We offer six key engagement models tailored to suit your specific needs and preferences.
We will quote as you request on API and FDF for the drug required.
We will take an agreed % of the upfront costs, normally 50%. Likewise, we will take an agreed ongoing share of the margin.
We will provide the agreed product at the agreed price. Credit will be given to SKPL ownership of the IP on the packaging in the designated market.
We will quote an amount to cover R&D/filing for commercial manufacture.
We will provide a unique formulation solution against a brief. Our quote for services can be agreed with some risk, reward upside while sharing costs. We may suggest equally a shared risk/reward on a % model.
we will agree on the scope of the scheme. With novel R&D in mind, we will devise the best solution.
Fees will be agreed at milestones or shared % exposure as in 2.